Literature DB >> 10755214

Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours.

J Komorowski1, J Jankewicz, H Stepień.   

Abstract

Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and soluble interleukin-2 receptor (sIL-2R) are important cytokines. They are secreted by normal pituitary glands and those with all types of adenomas and may be involved in pituitary tissue growth. The peripheral blood concentrations of VEGF, bFGF and sIL-2R in nineteen patients (17-70 years) with pituitary tumours and ten healthy subjects (23-34 years) were studied. Hypersecretion of prolactin (five cases), human growth hormone (four cases), and thyroid stimulating hormone (one case) was recorded in some patients, and the remaining subjects were diagnosed as having nonfunctional pituitary tumours. Increased peripheral blood plasma levels of VEGF (310.82 +/- 59.17 pg/ml) compared with controls (40.32 +/- 11.80 pg/ml; p < 0.01), as well as bFGF (87.27 +/- 7.58 pg/ml) versus controls (11.14 +/- 2.43 pg/ml; p < 0.001) were recorded. The levels of sIL-2R did not differ between the pituitary tumour patients (4,490.58 +/- 581.50 pg/ml) and control subjects (3,617.01 +/- 1,397.18 pg/ml; p > 0.05). The concentrations of VEGF and bFGF in the peripheral blood are useful additional markers of the presence of tumours.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755214

Source DB:  PubMed          Journal:  Cytobios        ISSN: 0011-4529


  12 in total

1.  Modulation of VEGF/Flk-1 receptor expression in the rat pituitary GH3 cell line by growth factors.

Authors:  Matilde Lombardero; Sergio Vidal; Robert Hurta; Alba Román; Kalman Kovacs; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

2.  Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas.

Authors:  Anna Gruszka; Jolanta Kunert-Radek; Marek Pawlikowski; Henryk Stepien
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  VEGF and CD31 association in pituitary adenomas.

Authors:  Carolina Cristina; María Inés Perez-Millan; Guillermina Luque; Raúl Ariel Dulce; Gustavo Sevlever; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

4.  Purification, partial characterization, crystallization and preliminary X-ray diffraction of a novel cardiotoxin-like basic protein from Naja naja atra (South Anhui) venom.

Authors:  Hui Rong; Yan Li; Xiao-hua Lou; Xio Zhang; Yong-xiang Gao; Mai-kun Teng; Li-wen Niu
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-01-27

Review 5.  Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour.

Authors:  N Garcia de la Torre; H E Turner; J A H Wass
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

6.  Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.

Authors:  María Susana Mallea-Gil; Carolina Cristina; María Inés Perez-Millan; Ana M Rodriguez Villafañe; Carolina Ballarino; Graciela Stalldecker; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

7.  Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors.

Authors:  Katsuhiro Miyajima; Susumu Takekoshi; Johbu Itoh; Kochi Kakimoto; Takashi Miyakoshi; Robert Yoshiyuki Osamura
Journal:  Acta Histochem Cytochem       Date:  2010-04-07       Impact factor: 1.938

8.  Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668.

Authors:  Hong Zhang; Andrew C Issekutz
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

9.  STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis.

Authors:  Xinhai Yang; Kristy Meyer; Andreas Friedl
Journal:  J Biol Chem       Date:  2013-06-02       Impact factor: 5.157

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.